Treatment of ITP With Rituximab and / or Accutane
Immune Thrombocytopeniaa prospective, multicenter, randomized, open-label, Phase II, two arms interventional trial performed in 5 departments of hematology in China
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
PurpuraThrombocytopenic2 moreThe project was undertaking by Qilu Hospital of Shandong University and other 18 well-known hospitals in China. In order to report the efficacy and safety of decitabine combining with dexamethasone for the treatment of adults with immune thrombocytopenia (ITP), compared to dexamethasone alone .
Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Immune ThrombocytopeniaThe purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus...
Immune ThrombocytopeniaThe project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia...
Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia and Autoimmune ThrombocytopeniaPatients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged 18 to 80 will be included in this study. The treatment regimen is a single dose anti-CD20 antibody (500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The treatment course would be repeated three months later.
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura...
Autoimmune Thrombocytopenic PurpuraThis study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
Immune ThrombocytopeniaThe project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).
A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP
Primary Immune Thrombocytopenic PurpuraTo select a dose and to make a decision for Phase 3 study
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia...
Immune ThrombocytopeniaIn this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)...
Primary Immune ThrombocytopeniaPrimary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. In most cases, platelet count is negatively correlated with the severity of bleeding. Correcting low platelets is the main measure to prevent bleeding in patients with ITP. Both rhTPO and eltrombopag act on TPO receptors to increase platelets.Which one will have a better short-term (2 weeks) effect to improve platelets is the purpose of the investigator's research.